Roche’s Entrectinib Differentiates Itself From NSCLC Competitors With CNS Data

Roche’s investigational non-small cell lung cancer candidate entrectinib has shown to reduce tumors in people with ROS1-positive NSCLC, including those whose disease had spread to the central nervous system, differentiating it from potential competitors.

Results from the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA trials show that Roche's entrectinib shrank tumors in 77% of people with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

Entrectinib, a tyrosine kinase inhibitor being developed for tumors that harbor NTRK or ROS1 fusions, also demonstrated a durable response of more than two years. Entrectinib was shown to shrink tumors in more than half of people with cancer in the central nervous system

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

19 May 2025

• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.